Novavax shifts Nuvaxovid commercialization to partners, links with Mabion
Novavax said commercialization will be led by Sanofi for Nuvaxovid in the US, EU and Canada, with Takeda in Japan, while expanding manufacturing ties with Mabion SA. The company also secured about $800M from Pfizer/Sanofi plus up to $200M in Sanofi milestones.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.